Detalles de la búsqueda
1.
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
Oncologist
; 22(3): 264-271, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28209746
2.
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
J Clin Oncol
; 42(15): 1738-1744, 2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38422473
3.
Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme.
Int J Radiat Oncol Biol Phys
; 69(3): 831-8, 2007 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17560737
4.
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.
J Clin Oncol
; 35(3): 343-351, 2017 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-27918718
5.
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
J Clin Oncol
; 22(1): 157-65, 2004 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-14701778
6.
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
J Clin Oncol
; 21(13): 2529-36, 2003 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12829672
7.
Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme.
J Clin Pharmacol
; 45(3): 299-312, 2005 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-15703365
8.
Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program.
PLoS One
; 10(10): e0139679, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26445503
9.
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.
Clin Cancer Res
; 20(17): 4488-98, 2014 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24687921
10.
Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer.
Clin Colorectal Cancer
; 12(3): 218-22, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23810377
11.
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
J Clin Oncol
; 31(32): 4105-14, 2013 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24101053
12.
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
J Clin Oncol
; 29(10): 1252-60, 2011 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21383283
13.
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
J Clin Oncol
; 28(25): 3917-21, 2010 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20679610
14.
Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.
Leuk Lymphoma
; 50(12): 1977-82, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19860624
15.
Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
J Thorac Oncol
; 2(8): 745-50, 2007 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-17762342
Resultados
1 -
15
de 15
1
Próxima >
>>